The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania brings together researchers investigating the causes and mechanisms of neurodegenerative diseases that occur more frequently with advancing age.
Diseases being studied include:
- Alzheimer's disease (AD)
- Parkinson's disease (PD)
- other Lewy Body Disorders (LBD)
- Frontotemporal Lobar Degeneration (FTD)
- Frontotemporal Disease with Parkinsonism (FTDP-17)
- Amyotrophic Lateral Sclerosis (ALS)
- Primary Lateral Sclerosis (PLS)
- other Motor Neuron Diseases
Virginia M.-Y. Lee, PhD, MBA and John Q. Trojanowski, MD, PhD founded and co-directed CNDR until 2002 when Dr. Lee assumed the role of Director, with Dr. Trojanowski as Co-Director.
Together, Drs. Lee and Trojanowski lead a team of over 50 University of Pennsylvania researchers, including Penn undergraduates, School of Medicine graduate students, postdoctoral fellows, technicians, and research associates, on a variety of projects that are funded by several NIH and foundation grants.
With laboratories located on three floors of the Hospital of the University of Pennsylvania's Maloney Building (floors 1, 3 and 6), CNDR is in the heart of Penn's campus. CNDR scientists also collaborate with researchers from Penn and other institutions around the globe to find better ways to diagnose and treat neurodegenerative disorders.
The mission of CNDR is to promote and conduct multidisciplinary clinical and basic research to increase understanding of the causes and mechanisms leading to brain dysfunction and degeneration in AD, PD, LBD, FTD, ALS, PLS, MND, and related disorders that occur increasingly with advancing age. The overarching goal is to find better ways to diagnose and treat these disorders. Implicit in this mission is a commitment to training the next generation of researchers.
Founded in 1991, CNDR became the first and only National Institutes of Health (NIH)-funded Alzheimer's Disease Core Center (ADCC) in the Delaware Valley, part of a network of 29 cooperating NIH-funded centers throughout the nation. CNDR continues to lead the Penn ADCC and in 2007 launched the NIH-funded Morris K. Udall Parkinson's Disease Research Center of Excellence at Penn.
More than 20 years ago, the team identified the significance of tau in Alzheimer's disease, later identifying TDP-43's role in other neurodegenerative diseases. Most recently, the team has shown, first in Parkinson's, how pathology spreads from cell-to-cell in neurodegenerative diseases.
Since its founding, CNDR has contributed to a dramatic expansion in basic and clinical research programs on neurodegenerative disorders at Penn. CNDR provides leadership, training/education, and core support to augment and enhance ongoing collaborative studies as well as to stimulate new investigations into the etiology, pathogenesis, diagnosis, treatment, and prevention of neurodegenerative diseases - and to translate progress in the lab to clinical practice. Researchers pursue a comprehensive array of research activities that extend from basic science methods of test tubes and cell culture systems to those involving animal models of neurodegenerative diseases.